In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report), with a price target of $10.00.
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Aquestive Therapeutics’ progress with Anaphylm, a novel epinephrine product. The company is nearing the completion of the regulatory submission process for Anaphylm, which has shown clinical results comparable to existing autoinjectors like EpiPen. The successful completion of adult clinical trials and positive feedback from the FDA in pre-NDA meetings bolster confidence in the product’s potential approval. Additionally, the pediatric trial results align with expectations, further supporting the NDA submission.
Selvaraju also highlights the strategic preparations Aquestive is making for the potential launch of Anaphylm. The company’s efforts to optimize market access and raise awareness through medical forums are crucial steps in ensuring a successful product introduction. With the NDA classified under the 505(b)(2) pathway, the anticipated 10-month review period could expedite the approval process. Aquestive’s commitment to independently launching Anaphylm in the U.S. and its planned promotional activities are expected to capitalize on the product’s rapid action and the substantial target market, reinforcing the Buy rating.
In another report released on March 7, Raymond James also maintained a Buy rating on the stock with a $7.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com